跳至正文
首页 » Blog » The internationalization of Chinese pharmaceutical enterprises, Japan, Europe and the United States market fully analyzed

The internationalization of Chinese pharmaceutical enterprises, Japan, Europe and the United States market fully analyzed

      

    In recent years, The internationalization impulse of Chinese pharmaceutical companies has become more and more obvious, going to Japan, the United States and Europe. But is the international market as rich and silver as Chinese pharmaceutical companies imagine? Shen Yaping, deputy general manager of Jiangsu Hengrui Pharmaceutical Co., LTD., analyzed the international market trend for the guests at the 31st National Pharmaceutical Industry Information Annual Meeting held by China Pharmaceutical Industry Information Center.

    According to the data provided by IMS, in the next five years, the compound growth rate of the global pharmaceutical market will remain at 47%, and the total value of the global pharmaceutical market will reach 1.25 trillion US dollars in 2018. The US market still accounts for 1/4 of the global market, while the growth rate of developed markets is relatively low, about 2% to 5%. Other emerging markets have a very high compound growth rate, and the secondary market growth rate is very high, basically emerging markets can grow at 9 to 10 percent.

    According to the division, north American market share of the generics market now at about $64.6 billion, Europe is the size of the $46 billion, slightly smaller than actually scale nearly billions of Japan, but its fledgling in generic drugs, sales is lower, but all aspects of the requirements about the quality of the drug is very strict, such as the original drug is more strict than the European Union and the United States.

    Ya-ping shen thought, therefore, to generics firms, aiming at target or Europe and the United States, although generic sales proportion is not high, but in developed markets at present consumption of drugs are generic drugs, 90% in the U.S. are generic drugs, the real reason is that the original drugs is very, very high price, it also led to the government’s huge financial pressure. To promote national health insurance, governments everywhere are encouraging generics, which make up more than 50% of all developed countries except Japan.

    The Japanese market is the most special

    In the most special of the Japanese market because the Japanese government burden of most of the medical expenses, personal spending only a small part, as residents medical costs each month over a certain limit under the condition of the government will put more than pay the part again, in this case, of course, every patient wants to use the latest drug, basically everyone in the country are hoping to use the original drug, The government is under great financial pressure, so Japan will force original manufacturers to reduce the price of drugs, so the proportion of original drugs used in Japan is particularly high.

    Even so, the Japanese government’s financial pressure is very big, so basically now he’s going to 2018, the government is encouraging the use of generic drugs to reach 35%, 35% is what concept, its sales of generic drugs will be 5.4 billion yuan from the recent growth in the range of between $184 to $20 billion, so its growth is very breathtaking, It is the fastest-growing generics of any developed country.

    If the financial pressure of the Japanese government is not relieved, the proportion of generic drugs is likely to increase further. When the proportion of generic drugs reaches 50%, the amount will reach 25 billion to 27 billion, and the sales will exceed 30 billion dollars if the proportion of generic drugs increases significantly like in the United States. So Japan is a very scary market for growth in the future.
    FDA inspections are gradually increasing

    Shen also reminded Chinese drug companies that FDA has been improving its inspection efforts in recent years. Although generic drugs in the US market have been dominated by Israeli companies in recent years, there have been many quality problems. This year, FDA officials also revealed that 60% of FDA’s overseas inspections are in India, and many problems have also been found. Several Indian companies have had their product lines denied entry to the U.S. market by the FDA.

    This means that if The product quality of Chinese enterprises is excellent, they will win in this competition and gradually improve the international image of Chinese pharmaceutical enterprises. At a time when most of the injection lines in India have been shut down by the FDA, it is not impossible for high-quality and stable injection manufacturers to be recognized by the FDA. (From CPHL Pharmaceutical Online)

    发表回复

    您的电子邮箱地址不会被公开。 必填项已用 * 标注